FOXP3 and colorectal carcinoma: The effect of Treg on patient outcome in CRC has until recently been contradictory [8, 10, 16, 17] but a recent publication by Saito et al. has shed light on this controversy, indicating two different CD4+Foxp3+ T cell populations of which only one comprise truly suppressive Treg.